Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Blood-derived biomarkers for brain and spinal cord diseases are urgently needed. The
introduction of highly sensitive immunoassays led to a rapid increase in the number of …
introduction of highly sensitive immunoassays led to a rapid increase in the number of …
Blood‐based biomarkers for Alzheimer's disease
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum
Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
C Cicognola, S Janelidze, J Hertze… - Alzheimer's research & …, 2021 - Springer
Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
IMW Verberk, E Thijssen, J Koelewijn, K Mauroo… - Alzheimer's research & …, 2020 - Springer
Background Blood-based biomarkers for Alzheimer's disease (AD) might facilitate
identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation …
identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation …
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
Background Increasing evidence supports the use of plasma biomarkers of
neurodegeneration and neuroinflammation to screen and diagnose patients with dementia …
neurodegeneration and neuroinflammation to screen and diagnose patients with dementia …
Cerebral iron deposition in neurodegeneration
Disruption of cerebral iron regulation appears to have a role in aging and in the
pathogenesis of various neurodegenerative disorders. Possible unfavorable impacts of iron …
pathogenesis of various neurodegenerative disorders. Possible unfavorable impacts of iron …
Potential role of chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) in neurodegeneration and Alzheimer's disease
K Connolly, M Lehoux, R O'Rourke… - Alzheimer's & …, 2023 - Wiley Online Library
Abstract Chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) has long been known as a biomarker
for early detection of neuroinflammation and disease diagnosis of Alzheimer's disease (AD) …
for early detection of neuroinflammation and disease diagnosis of Alzheimer's disease (AD) …
Cerebrospinal fluid biomarkers of Alzheimer's disease: current evidence and future perspectives
Alzheimer's disease is a progressive, clinically heterogeneous, and particularly complex
neurodegenerative disease characterized by a decline in cognition. Over the last two …
neurodegenerative disease characterized by a decline in cognition. Over the last two …
Diagnostic value of the CSF α-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies
Objective To investigate whether the CSF α-synuclein (α-syn) real-time quaking-induced
conversion (RT-QuIC) assay accurately identifies patients with mild cognitive impairment …
conversion (RT-QuIC) assay accurately identifies patients with mild cognitive impairment …